BACKGROUND: Acute myeloid leukemia (AML) is the common form of acute leukemia in adults, accounting for over 80% of all acute leukemias in individuals aged >18 years. Overall 5-year survival remains poor in older AML patients; it is <5% in patients aged >65 years. In this study, the authors examined whether survival has improved for subsets of geriatric AML patients over 3 successive decades. METHODS: Surveillance, Epidemiology and End Results (SEER) data were used to determine trends in relative survival by age among 19,000 patients with AML over 3 successive decades (1977-1986, 1987-1996, and 1997-2006). Relative survival rates (RRs) with 95% confidence intervals (CIs) were calculated as measures of survival. RESULTS: Overall, the RRs increased for each successive decade (1977-1986, 1987-1996, and 1997-2006) in patients ages 65 to 74 years, with improvements in 12-month survival from 20%, to 25%, to 30%, respectively. Findings were similar for 24-month, 36-month, 48-month, and 60-month survival. However, survival rates did not improve in patients aged ≥75 years. The oldest old patients (aged ≥85 years) had the lowest survival rates, with no apparent improvement. CONCLUSIONS: This analysis of a large data set demonstrated that, although overall survival remained unsatisfactory among older patients, it improved in the younger old (ages 65-74 years). Survival of older old AML patients has not been favorably impacted by available AML therapies or supportive care, and intervention in this age group is best undertaken on a clinical trial.
BACKGROUND:Acute myeloid leukemia (AML) is the common form of acute leukemia in adults, accounting for over 80% of all acute leukemias in individuals aged >18 years. Overall 5-year survival remains poor in older AMLpatients; it is <5% in patients aged >65 years. In this study, the authors examined whether survival has improved for subsets of geriatric AMLpatients over 3 successive decades. METHODS: Surveillance, Epidemiology and End Results (SEER) data were used to determine trends in relative survival by age among 19,000 patients with AML over 3 successive decades (1977-1986, 1987-1996, and 1997-2006). Relative survival rates (RRs) with 95% confidence intervals (CIs) were calculated as measures of survival. RESULTS: Overall, the RRs increased for each successive decade (1977-1986, 1987-1996, and 1997-2006) in patients ages 65 to 74 years, with improvements in 12-month survival from 20%, to 25%, to 30%, respectively. Findings were similar for 24-month, 36-month, 48-month, and 60-month survival. However, survival rates did not improve in patients aged ≥75 years. The oldest old patients (aged ≥85 years) had the lowest survival rates, with no apparent improvement. CONCLUSIONS: This analysis of a large data set demonstrated that, although overall survival remained unsatisfactory among older patients, it improved in the younger old (ages 65-74 years). Survival of older old AMLpatients has not been favorably impacted by available AML therapies or supportive care, and intervention in this age group is best undertaken on a clinical trial.
Authors: K R Rai; J F Holland; O J Glidewell; V Weinberg; K Brunner; J P Obrecht; H D Preisler; I W Nawabi; D Prager; R W Carey; M R Cooper; F Haurani; J L Hutchison; R T Silver; G Falkson; P Wiernik; H C Hoagland; C D Bloomfield; G W James; A Gottlieb; S V Ramanan; J Blom; N I Nissen; A Bank; R R Ellison; F Kung; P Henry; O R McIntyre; S K Kaan Journal: Blood Date: 1981-12 Impact factor: 22.113
Authors: D L Stirewalt; K J Kopecky; S Meshinchi; F R Appelbaum; M L Slovak; C L Willman; J P Radich Journal: Blood Date: 2001-06-01 Impact factor: 22.113
Authors: C P Leith; K J Kopecky; J Godwin; T McConnell; M L Slovak; I M Chen; D R Head; F R Appelbaum; C L Willman Journal: Blood Date: 1997-05-01 Impact factor: 22.113
Authors: J Yates; O Glidewell; P Wiernik; M R Cooper; D Steinberg; H Dosik; R Levy; C Hoagland; P Henry; A Gottlieb; C Cornell; J Berenberg; J L Hutchison; P Raich; N Nissen; R R Ellison; R Frelick; G W James; G Falkson; R T Silver; F Haurani; M Green; E Henderson; L Leone; J F Holland Journal: Blood Date: 1982-08 Impact factor: 22.113
Authors: S S Kenderian; M Ruella; O Shestova; M Klichinsky; V Aikawa; J J D Morrissette; J Scholler; D Song; D L Porter; M Carroll; C H June; S Gill Journal: Leukemia Date: 2015-02-27 Impact factor: 11.528